Blood pressure medication recall expands again to include losartan

Grant Boone
March 5, 2019

The recalled medication is half of a giant class of medicine referred to as angiotensin II receptor blockers, or ARBs, which work by enjoyable the blood vessels.

Camber Pharmaceuticals is voluntarily recalling 87 lots of the blood pressure drug Losartan due to traces of a potential carcinogen.

And then there's Macleods Pharmaceuticals Limited, which announced on February 22, 2019, that it was initiating a recall on just one of its lots of Losartan tablets after traces of NDEA were detected by officials.

It added that it, too, "has not received any reports of adverse events related to this recall".

Recent federal research has found NDMA and NDEA's "risk to individual patients is very low", a U.S. Food and Drug Administration statement said.

Packaged in 30-count, 90-count, 500-count and 1,000-count bottles, the recalled drugs contain the following National Drug Codes on their labels: Losartan 25 mg 31722-700-90, 31722-700-05, 31722-700-10; Losartan 50 mg 31722-701-30, 31722-701-90, 31722-70-10; and Losartan 100 mg 31722-702-30, 31722-702-90, and 31722-702-10.

Chelsea defender Rudiger: Sarri has changed after Man City loss
We didn't kill the match and then in the last 20-25 minutes we were really very exhausted - physically but also mentally. The performance was great and we took three points.

Camber's recall is the second in a week of Losartan tablets. The affected Losartan tablets have expiration dates that range from September 2019 to June 2020. Prinston Pharmaceutical identified China's Zhejiang Huahai Pharmaceuticals as the source of NDEA found in its hypertension medication recalled by the company last month.

The FDA has said it thinks the potential carcinogens, known as nitrosamine impurities, are a result of the manufacturing processes the companies used.

"Our ongoing effort has determined that the impurities may be generated by specific chemical reactions in the manufacturing process of the drug's active pharmaceutical ingredients", said FDA Commissioner Scott Gottlieb, M.D., in a statement.

From a community pharmacy perspective, this recall has been hard because many pharmacies don't keep the lot numbers of medications after they're dispensed, Freeman said: "That information is not tracked effectively".

Here's a list of the Torrent Pharmaceuticals products being recalled.

Other reports by

Discuss This Article